Pain Matters Podcast Network · AAPM - American Academy of Pain Medicine

Exploring Addiction Myths and Harm Reduction with Maia Szalavitz*

·54 min·3 clips

Methadone and buprenorphine are the only treatments Szalavitz says cut overdose death rates by half or more.

The episode turns on a basic but consequential distinction between dependence and addiction. Maia Szalavitz argues that the field has spent too many years collapsing those ideas into one another. She points back to the 1980s, when cocaine was described as not addictive because it did not produce physical dependence. That model was wrong then and remains harmful now. It makes methadone maintenance look like continued addiction even when a patient has regained stability, work, and family life. It also causes trouble for people on other medications, including Prozac and long-term opioids for chronic pain. If every physical reliance is treated as addiction, the clinical and legal consequences get muddled fast. The conversation treats that as more than a semantic issue. It is a framework problem that changes how patients are judged and how doctors are expected to act. From there, the discussion moves into emerging data on Ozempic and similar drugs. Szalavitz describes large medical-record studies suggesting lower overdose rates among people with opioid use disorder who were taking these medications for diabetes or obesity. She also notes reductions in alcohol use. The same line of inquiry points toward less compulsive behavior more broadly, including patterns people often describe as gambling or sexual compulsivity. The explanation offered is mechanistic rather than moral. These drugs may be acting on the brain system involved in wanting. Dopamine is part of that circuit. The goal, as she frames it, is not to eliminate desire. The useful effect would be reducing compulsive wanting while preserving the ordinary appetite to eat, work, and live. That is also why the episode resists the social-media idea of dopamine rest. Szalavitz says that framing is too simple to be useful. Parkinson's disease is used as the counterexample that shows why dopamine should not be treated like a wellness slogan. The conversation keeps the focus on evidence rather than trend language. It separates theory from settled practice. It also leaves room for uncertainty, because some of the randomized data are still only beginning to arrive. Even so, the discussion is not bleak. It ends with a cautious sense that pain and opioid care may be moving away from the hardest pendulum swings. The result is an interview that is clinical without becoming cold, and skeptical without becoming dismissive.

As heard by us

A measured case for separating dependence from addiction, with a useful look at craving science and compulsive behavior.

The episode draws a clear line between dependence and addiction, and it makes the case that collapsing every physical reliance into substance use disorder has caused real harm.

Read the full review in PlayNext →

Why you'd press play

You want a cleaner map of addiction than the usual moral shorthand.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Pain Matters Podcast Network